New Guidelines on Migraine Prevention Medications Released by AAN and AHS

On August 31, 2026, the American Academy of Neurology (AAN) and the American Headache Society (AHS) unveiled updated practice guidelines aimed at improving the prevention of migraines in adults. This significant revision is a follow-up to the 2012 guideline and has been published in Neurology and Headache, the respective official journals of the AAN and AHS.

Understanding Migraines

Migraines are not merely severe headaches; they are chronic brain disorders characterized by recurrent attacks that can come with various debilitating neurological symptoms. These include not just pain, but also nausea, sensitivity to light and sound, dizziness, and cognitive impairment, all of which can severely impact a person's daily life. Attack durations vary, often lasting anywhere from a few hours to several days.

Considering the prevalence of migraines, which leads many to seek the care of neurologists and primary care physicians alike, the new guidelines serve as a crucial resource for healthcare professionals striving to deliver optimal care to patients suffering from this condition.

Key Updates in the Guideline

The refreshed guidelines articulate clear recommendations for preventive treatments, particularly emphasizing their use in cases where patients experience four or more migraine days monthly or exhibit significant headache symptoms that impair daily functions. The recommendation is rooted in recent research developments, which have broadened the scope of treatment options available to clinicians and patients.

Tamara Pringsheim, MD, who contributed to the guideline, stressed the importance of a diversified medication approach, highlighting that various categories of drugs can offer effective prevention against migraine attacks. These options range from newer classes of medications to older, established treatments.

Rebecca C. Burch, MD, another author of the guideline, elaborated on the flexibility in medication options, indicating that if one type doesn't yield results, another could still be effective. The guidelines are structured to encourage a shared decision-making process between clinicians and their patients, ensuring that patients are well-informed about the different preventive strategies available.

Considering the Patient's Quality of Life

A critical focus of this guideline is to prioritize the patient's quality of life when selecting preventive medications. Clinicians are urged to evaluate how migraines impact their patients' workability and life satisfaction. Furthermore, it suggests discussing various options with patients, including potential side effects, costs, and types of medications, whether they are taken orally or via injectable form.

The guideline also recommends that clinicians reassess treatment effectiveness at designated timeframes to ensure patients are receiving the optimal care they require.

Conclusion

The new practice guidelines from AAN and AHS represent a significant step toward enhancing migraine care. With a growing understanding of migraines as complex neurological conditions, these updated standards provide a comprehensive framework for clinicians to follow. In doing so, AAN and AHS are not only empowering healthcare providers but ultimately improving the lives of individuals affected by this challenging disorder.

Migraine remains one of the leading reasons for consultations with neurologists, making these updated guidelines particularly timely. As the AAN and AHS work together to implement these practices, they hope to see an improvement in both the frequency and severity of migraine attacks, allowing for more individuals to lead healthier, fuller lives.

For more resources on migraine management, visit BrainHealth.com, a valuable platform offering expert-reviewed information and support for those affected by migraine and other neurological conditions.